Entities / Company
Axsome Therapeutics.
American biopharmaceutical company
- Reports this week
- 1
- Active events
- 0
- Connections
- 36
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Gone quiet
No new reports in 90+ days-
H.C. Wainwright reaffirmed a Buy rating on Axsome Therapeutics on September 2, 2025.Some support2 reports
-
Axsome Therapeutics and Revolution Medicines, Inc. are competing in the specialized biotech market.Some support2 reports
-
Axsome Therapeutics CEO Herriot Tabuteau sold significant company shares, with the transaction disclosed via filings with the SEC.Some support1 report
-
Royal Bank of Canada raised its price objective for Axsome Therapeutics stock.Some support1 report
-
Axsome Therapeutics hosted its R&D Day at a Frontiers event in New York City on July 7, 2025.Some support2 reports
-
Axsome Therapeutics raised awareness of Alzheimer's impact in the US on June 20, 2025.Speculative1 report
-
Insider Hunter R. Murdock sold shares of Axsome Therapeutics worth $1,370,647 on June 24, 2025.Speculative1 report
-
Axsome Therapeutics plans to submit a New Drug Application (NDA) to the FDA. Herriot Tabuteau is the CEO of the company.Well supported7 reports
-
Morgan Stanley assumed coverage of Axsome Therapeutics with an Overweight rating on July 6, 2025.Speculative1 report
-
Axsome Therapeutics uses LinkedIn for company presence and requires FDA approval for its products.Some support2 reports
-
Both Axsome Therapeutics and Shopify were identified as attractive investment opportunities on July 24, 2025.Some support1 report
-
Axsome Therapeutics reported strong sales uptake of its drugs Auvelity and Sunosi in the US.Well supported4 reports
No events began in the chosen period. Widen it, or reset.
Around Axsome Therapeutics this week
News at the entities that move Axsome Therapeutics most-
FDA StructuralISO standards are influencing regulatory requirements across the industry.Moves Axsome Therapeutics
-
Mark Jacobson StructuralMark Jacobson models the shift toward renewable energy in Canada.Moves Axsome Therapeutics
-
Royal Bank of Canada TransactionalRBC announced card enhancements in Toronto on November 2, 2026.Moves Axsome Therapeutics
-
Benzinga Mentioned togetherAbbVie's CEO, Robert A. Michael, is linked to pre-IPO investments, with Benzinga reporting financial data and Kevin O'Leary commenting on strategies.Moves Axsome Therapeutics
-
SEC StructuralPagaya technologies stock traded on the electronic exchange and required stock sales disclosures with the SEC on July 2, 2026.Moves Axsome Therapeutics
-
Nasdaq StructuralRedHill Biopharma Ltd., headquartered in Tel Aviv, is a company publicly traded on the Nasdaq exchange with its lead product approved by the FDA.Moves Axsome Therapeutics
Connections
The 11 strongest of 36, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
FDA Structural
A company's product viability is structurally dependent on formal regulatory review, approval, and oversight by the FDA.
-
Mark Jacobson Structural
Mark Jacobson serves as the Chief Operating Officer of Axsome Therapeutics.
-
Herriot Tabuteau Structural
Herriot Tabuteau serves as the Chief Executive Officer of Axsome Therapeutics.
-
SEC Structural
A operates under the regulatory oversight and disclosure requirements of B.
-
Nasdaq Structural
Axsome Therapeutics is a company formally listed on the Nasdaq exchange.
-
Royal Bank of Canada Transactional
Royal Bank of Canada raised price objective on Axsome Therapeutics stock.
-
Benzinga Mentioned together
Benzinga, a financial news platform, reports on Axsome Therapeutics' market ratings and developments.
-
Mark Coleman Transactional
Mark Coleman sold shares of Axsome Therapeutics on 2026-07-18.
Show all 11 connections
-
LinkedIn Mentioned together
Axsome Therapeutics utilizes LinkedIn for its corporate presence and communication.
-
New York City Shared context
Axsome Therapeutics is headquartered and conducts R&D activities in New York City.
-
MarketBeat Mentioned together
MarketBeat is a technology platform that tracks average stock ratings, providing general market context.
History
Events by the month they beganJuly 2026
2 eventsJune 2026
10 events- H.C. Wainwright reaffirmed a Buy rating on Axsome Therapeutics on September 2, 2025.
- Royal Bank of Canada raised its price objective for Axsome Therapeutics stock.
- Axsome Therapeutics hosted its R&D Day at a Frontiers event in New York City on July 7, 2025.
- Axsome Therapeutics raised awareness of Alzheimer's impact in the US on June 20, 2025.
- Insider Hunter R. Murdock sold shares of Axsome Therapeutics worth $1,370,647 on June 24, 2025.
- Axsome Therapeutics plans to submit a New Drug Application (NDA) to the FDA. Herriot Tabuteau is the CEO of the company.
- Morgan Stanley assumed coverage of Axsome Therapeutics with an Overweight rating on July 6, 2025.
- Axsome Therapeutics uses LinkedIn for company presence and requires FDA approval for its products.
- Both Axsome Therapeutics and Shopify were identified as attractive investment opportunities on July 24, 2025.
- Axsome Therapeutics reported strong sales uptake of its drugs Auvelity and Sunosi in the US.